Home ETF List About

ETF Holdings Breakdown of PCVX

Stock NameVaxcyte Inc
TickerPCVX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS92243G1085
LEI254900M7NMHTGASX8D95

PCVX institutional holdings

The following institutional investment holdings of PCVX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-17 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 64,471USD 2,732,926
2025-10-17 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 82,397USD 3,492,809
2025-10-17 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 82,397USD 3,492,809
2025-10-17 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 81,670USD 3,461,991 -3.7%
2025-10-17 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 1,610USD 68,248 -3.7%
Total =312,545 USD 13,248,783
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with PCVX

Vaxcyte, Inc. (NASDAQ:PCVX) Receives $106.25 Average Price Target from Analysts
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) has received an average rating of “Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The […] - 2025-09-16 02:32:42
Swiss National Bank Has $8.21 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)
Swiss National Bank reduced its holdings in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 0.8% in the 1st quarter, HoldingsChannel reports. The fund owned 217,300 shares of the company’s stock after selling 1,700 shares during the period. Swiss National Bank’s holdings in Vaxcyte were worth $8,205,000 at the end of the most recent quarter. Several […] - 2025-08-17 05:55:01
Natixis Advisors LLC Decreases Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)
Natixis Advisors LLC lowered its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 5.7% during the first quarter, Holdings Channel reports. The institutional investor owned 14,649 shares of the company’s stock after selling 888 shares during the period. Natixis Advisors LLC’s holdings in Vaxcyte were worth $553,000 at the end of the […] - 2025-08-12 04:38:46
KLP Kapitalforvaltning AS Buys 500 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)
KLP Kapitalforvaltning AS increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 2.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,000 shares of the company’s stock after purchasing an additional 500 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Vaxcyte […] - 2025-07-29 06:16:55
Universal Beteiligungs und Servicegesellschaft mbH Buys 3,634 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)
Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 3.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 107,317 shares of the company’s stock after buying an additional 3,634 shares during the quarter. Universal […] - 2025-07-29 05:22:57
Brokerages Set Vaxcyte, Inc. (NASDAQ:PCVX) Target Price at $136.50
Shares of Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) have been given a consensus rating of “Buy” by the ten ratings firms that are covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month […] - 2025-07-28 02:30:52
New York State Common Retirement Fund Increases Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)
New York State Common Retirement Fund increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 190.6% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 137,440 shares of the company’s stock after purchasing an additional 90,145 shares during the quarter. New York […] - 2025-07-22 07:09:01
Principal Financial Group Inc. Has $17.73 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)
Principal Financial Group Inc. raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 52.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 469,561 shares of the company’s stock after acquiring an additional 160,622 shares during the period. […] - 2025-07-11 05:21:08
Calamos Advisors LLC Has $257,000 Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)
Calamos Advisors LLC decreased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 32.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 6,794 shares of the company’s stock after selling 3,201 shares during the period. Calamos Advisors LLC’s holdings in Vaxcyte were worth […] - 2025-07-08 05:46:54
Vaxcyte, Inc. (NASDAQ:PCVX) Holdings Lowered by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC trimmed its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 43.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 335,990 shares of the company’s stock after selling 257,533 shares during the […] - 2025-07-04 05:06:38
Analysts Set Vaxcyte, Inc. (NASDAQ:PCVX) Price Target at $136.50
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) has been given a consensus rating of “Buy” by the ten ratings firms that are covering the firm, Marketbeat.com reports. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among […] - 2025-07-03 02:42:45
Analyzing Vaxcyte (NASDAQ:PCVX) & Genenta Science (NASDAQ:GNTA)
Genenta Science (NASDAQ:GNTA – Get Free Report) and Vaxcyte (NASDAQ:PCVX – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Volatility & Risk Genenta Science has a beta of […] - 2025-06-13 02:32:52
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Average Rating of “Buy” from Brokerages
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) has earned an average recommendation of “Buy” from the ten analysts that are currently covering the stock, Marketbeat reports. Nine investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts […] - 2025-06-05 02:32:50
Head to Head Contrast: Vaxcyte (NASDAQ:PCVX) and Beam Therapeutics (NASDAQ:BEAM)
Vaxcyte (NASDAQ:PCVX – Get Free Report) and Beam Therapeutics (NASDAQ:BEAM – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends. Risk and Volatility Vaxcyte has a beta of 1.27, […] - 2025-05-30 02:28:51
Millennium Management LLC Sells 21,857 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)
Millennium Management LLC lessened its stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 7.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 276,578 shares of the company’s stock after selling 21,857 shares during the quarter. Millennium Management LLC owned approximately […] - 2025-05-21 05:46:50
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 115.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 293,706 shares of the company’s stock after buying an additional 157,277 shares during the period. Dimensional Fund Advisors LP’s holdings in Vaxcyte were worth $24,043,000 at the end of the […] - 2025-05-07 05:22:50
Mariner LLC Has $487,000 Position in Vaxcyte, Inc. (NASDAQ:PCVX)
Mariner LLC boosted its position in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 27.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 5,947 shares of the company’s stock after buying an additional 1,290 shares during the period. Mariner LLC’s holdings in Vaxcyte were worth $487,000 as of its most recent filing with the Securities […] - 2025-05-02 05:10:52
Renaissance Technologies LLC Purchases Shares of 54,077 Vaxcyte, Inc. (NASDAQ:PCVX)
Renaissance Technologies LLC acquired a new position in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 54,077 shares of the company’s stock, valued at approximately $4,427,000. A number of other hedge funds and other institutional investors […] - 2025-04-22 05:03:18
Norges Bank Acquires Shares of 1,100,286 Vaxcyte, Inc. (NASDAQ:PCVX)
Norges Bank bought a new position in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,100,286 shares of the company’s stock, valued at approximately $90,069,000. Norges Bank owned about 0.88% of Vaxcyte at the end of the most […] - 2025-04-03 05:36:54
Bank of America Lowers Vaxcyte (NASDAQ:PCVX) Price Target to $137.00
Vaxcyte (NASDAQ:PCVX – Get Free Report) had its price target reduced by research analysts at Bank of America from $157.00 to $137.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Bank of America‘s price objective would suggest a potential upside of 306.65% from the […] - 2025-04-03 04:24:52
Needham & Company LLC Has Lowered Expectations for Vaxcyte (NASDAQ:PCVX) Stock Price
Vaxcyte (NASDAQ:PCVX – Get Free Report) had its target price lowered by investment analysts at Needham & Company LLC from $140.00 to $90.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price target would suggest a potential upside of 167.14% from the […] - 2025-04-03 04:24:52
Proficio Capital Partners LLC Invests $2.92 Million in Vaxcyte, Inc. (NASDAQ:PCVX)
Proficio Capital Partners LLC purchased a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 35,609 shares of the company’s stock, valued at approximately $2,915,000. Several other large investors have also recently added to or reduced their stakes in the company. Whipplewood Advisors […] - 2025-03-19 05:44:45
PNC Financial Services Group Inc. Boosts Stake in Vaxcyte, Inc. (NASDAQ:PCVX)
PNC Financial Services Group Inc. increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 18.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,076 shares of the company’s stock after acquiring an additional 1,397 shares during the period. PNC Financial Services Group Inc.’s holdings […] - 2025-03-18 05:38:57
Victory Capital Management Inc. Has $24.85 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)
Victory Capital Management Inc. lifted its stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 19.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 303,556 shares of the company’s stock after purchasing an additional 48,516 shares during the quarter. Victory Capital Management Inc. owned […] - 2025-03-11 06:16:48
Brokerages Set Vaxcyte, Inc. (NASDAQ:PCVX) PT at $127.71
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) has been given a consensus recommendation of “Buy” by the nine ratings firms that are covering the company, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued ratings on the stock in the last […] - 2025-02-28 04:06:48
After-Hours Earnings Report for February 25, 2025 : INTU, WDAY, ALC, CPNG, AXON, EXR, KEYS, FSLR, CART, CAVA, PCVX, PR
The following companies are expected to report earnings after hours on 02/25/2025. Visit our Earnings Calendar for a full list of expected earnings releases.Intuit Inc. (INTU)is reporting for the quarter ending January 31, 2025. The computer software company's consensus earnings - 2025-02-25 17:00:00
Mirae Asset Global Investments Co. Ltd. Sells 1,747 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)
Mirae Asset Global Investments Co. Ltd. decreased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 11.6% during the fourth quarter, HoldingsChannel reports. The fund owned 13,264 shares of the company’s stock after selling 1,747 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Vaxcyte were worth $1,083,000 as […] - 2025-02-12 06:40:50
abrdn plc Increases Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)
abrdn plc increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 171.4% in the 4th quarter, HoldingsChannel reports. The fund owned 224,824 shares of the company’s stock after acquiring an additional 141,994 shares during the period. abrdn plc’s holdings in Vaxcyte were worth $18,404,000 at the end of the most recent quarter. Several […] - 2025-02-07 07:30:04
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by Chicago Partners Investment Group LLC
Chicago Partners Investment Group LLC increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 9.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,431 shares of the company’s stock after purchasing an additional 458 shares during […] - 2025-02-04 06:49:12
Vaxcyte, Inc. (NASDAQ:PCVX) Receives $145.71 Average Price Target from Analysts
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) has been given an average recommendation of “Buy” by the eight analysts that are currently covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last year is […] - 2025-02-03 04:08:51

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.